ADVFN US – Market Content Editor
-
Stellantis issues recall for more than 72,000 Ram trucks over dashboard display malfunction
Stellantis (NYSE:STLA) is pulling back 72,509 Ram vehicles in the U.S. after identifying a software fault that can cause the instrument cluster screen to shut off unexpectedly. The U.S. National Highway Traffic Safety Administration disclosed the recall on Monday, citing documentation provided by the manufacturer. According to the filing, a software malfunction can cause the…
-
Meta reportedly to face fresh EU scrutiny over WhatsApp’s AI rollout
Brussels is preparing to launch a new antitrust investigation into Meta Platforms Inc (NASDAQ:META) tied to the introduction of artificial intelligence tools inside WhatsApp, the Financial Times reported on Thursday. According to the report, which cited two officials familiar with the matter, the European Commission intends to examine how Meta embedded its Meta AI assistant…
-
Viridian wraps drilling at Kraken Zone
In this episode of the Capital Compass, we’re checking back in with Viridian Metals (USOTC:VIRMF), an explorer building momentum in one of the world’s most prospective emergent copper regions, Newfoundland and Labrador. The company has now completed drilling at the Kraken Main Zone, advancing one of the shallowest and most accessible copper targets in the province.…
-
U.S. Stocks Move Higher As Jobs Data Adds To Rate Cut Optimism
After showing a lack of direction early in the session, stocks moved mostly higher over the course of the trading day on Wednesday. While the Nasdaq and the S&P 500 posted modest gains, the narrower Dow showed a more notable move to the upside. The major averages all finished the day in positive territory. The…
-
Microsoft shares dip after report claims AI sales targets have been cut
Microsoft (NASDAQ:MSFT) slipped 2% in early Wednesday trading after The Information reported that the company has scaled back its sales quotas for certain AI software products amid slower-than-expected customer adoption. According to the report, Microsoft has tempered expectations for revenue growth from its newest AI “agents” — tools intended to automate multi-step workflows. Several business…
-
Uber shares climb as autonomous robotaxi service goes live in Dallas
Uber Technologies Inc. (NYSE:UBER) gained 2% in premarket trading Wednesday, while Nebius Group NV (NASDAQ:NBIS) — owner of Avride — added 1.4% after the two companies rolled out a new robotaxi service in Dallas. The launch enables riders in the city to be paired with an Avride autonomous vehicle when selecting UberX, Uber Comfort, or…
-
Delta warns government shutdown will cut Q4 profit by up to $200 million
Delta Air Lines (NYSE:DAL) said Wednesday that the recent U.S. government shutdown is expected to shave as much as $200 million off its pre-tax profit for the December quarter, an estimated hit of roughly $0.25 per share. Shares of the airline ticked up 0.7% in premarket trading despite the guidance update. Delta noted that while…
-
Ondas Holdings climbs after securing government deal for large-scale drone border security system
Ondas Holdings (NASDAQ:ONDS) gained 6% on Wednesday after revealing it has been awarded a major government contract to build and deploy an autonomous border surveillance and protection network powered by thousands of drones. Ondas Autonomous Systems (OAS) was selected as prime contractor following a competitive bidding process that included several leading defense firms. The company…
-
Kaixin Auto shares surge after unveiling $15M equity-funded acquisition
Kaixin Auto Holdings (NASDAQ:KXIN) jumped 27.7% in premarket trading Wednesday after announcing a new strategic acquisition that expands its footprint in China’s auto retail and wholesale market. On December 2, 2025, the company signed an agreement for its wholly owned subsidiary, Zhejiang Kaixin Auto Co., Ltd., to purchase 100% of Zhejiang Ordinary Smile Auto Sales…
-
Capricor jumps after DMD cell therapy succeeds in Phase 3 HOPE-3 study
Capricor Therapeutics (NASDAQ:CAPR) rallied 14.6% in premarket trading on Wednesday after the company reported encouraging topline data from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel for Duchenne muscular dystrophy (DMD). The placebo-controlled, double-blind study reached its primary goal, showing a 54% reduction in the rate of upper-limb functional decline (PUL v2.0) compared with placebo…